Therefore, more experiments in vivo and in vitro, as well as more clinical data, are needed to explore the exact role played by H19 regulating sensitivity to the various EGFR‐TKIs used in clinical treatment of lung cancer. This evidence concerns the gene H19 and lung cancer.